Veracyte opened lower at $51.54, compared with its previous close of $52.17. In the last trading session, the stock traded between $49.65 and $51.93. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Veracyte is now worth
$ 104.28
giving a profit of
$ 4.28 (4.28%)
Note: Past profits do not guarantee future returns.
Rating from 10 Analysts
Today's Change
$-2.24 (-4.30%)
Day High
$51.93
Day Low
$49.65
Day Open
$51.54
Prev Close
$52.17
Volume
3,41,113
1W Return
8.36%
1M Return
8.39%
3M Return
-10.38%
6M Return
57.11%
1Y Return
41.00%
Market Cap ($ Mn)
4,014
PE Ratio
30.94
PB Ratio
2.51
PEG Ratio
0.10
ROE
5.39%
ROCE
4.35%
EPS (TTM)
$0.32
1 Week
8.36%
1 Month
8.39%
3 Months
-10.38%
6 Months
57.11%
9 Months
28.88%
Veracyte secures Medicare coverage for Prosigna breast cancer test
Veracyte Inc secured Medicare coverage for its Prosigna Breast Risk of Recurrence test via Palmetto GBA MolDX. Coverage effective August 19, 2026, for postmenopausal women with early-stage ER+ breast cancer. Eligibility limited to stage I or II disease with 0-3 positive lymph nodes meeting Medicare criteria. Milestone follows June 2026 U.S. launch and aims to remove financial barriers for patient adoption.
14 days agoVeracyte Inc. Q3FY26 Results: Release date set for November 4
Veracyte Inc. will release Q3 2026 financial results on November 4, 2026. Conference call scheduled for 4:30 pm ET on the same day. Webcast replay will be available on the company website post-broadcast.
15 days agoVeracyte acquires Convergent Genomics for $150M upfront cash
Veracyte pays $150 million upfront to acquire Convergent Genomics. Deal includes up to $30 million in milestone payments tied to reimbursement. Acquisition adds clinically validated UroAmp bladder cancer diagnostics. Target addresses 65,000 annual NMIBC diagnoses in the U.S. No update to 2026 adjusted EBITDA guidance as expenses were pre-accrued.
1mo agoVeracyte posts 15% revenue surge in Q2, raises FY26 guidance
Veracyte delivered strong Q2 2026 results with $150.3 million in revenue and $25.5 million in net income, driven by 15% revenue growth and new product launches. The company raised its full-year sales guidance to $590-596 million, citing robust demand for Decipher and Afirma tests.
3mo agoVeracyte Inc. to hold investor fireside chats in August and September
Veracyte Inc. will host fireside chats at the Canaccord Genuity and Morgan Stanley conferences on Aug. 11 and Sep. 15, respectively. Live webcasts and 90-day replays will be hosted on the company’s investor relations site, offering insights into its cancer diagnostics portfolio.
3mo agoPiper Sandler initiates Veracyte coverage with Overweight rating
Piper Sandler analyst David Westenberg initiated coverage on Veracyte Inc with an Overweight rating and a $66 price target, contrasting with Morgan Stanley's Underweight rating and $47 target. Veracyte shares closed at $56.62 on Tuesday.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $709.18 | +0.71% | $2,62,217.18M | 33.49 | |
| $236.98 | +1.24% | $1,66,722.78M | 38.52 | |
| $436.00 | +2.73% | $62,846.78M | - | |
| $181.15 | -0.18% | $51,071.44M | 30.34 | |
| $480.07 | +0.67% | $47,165.92M | 104.98 | |
| $575.98 | +2.32% | $45,376.28M | 39.00 | |
| $275.06 | -1.43% | $45,329.89M | 32.52 | |
| $290.06 | +0.44% | $43,799.06M | 40.22 | |
| $1,718.61 | +1.19% | $34,435.79M | 31.52 | |
| $368.16 | +2.20% | $29,857.78M | 27.72 | |
| $252.92 | +2.97% | $27,826.01M | 25.77 | |
| $185.31 | +1.49% | $24,867.86M | - |
An investment of $100 made 5 years ago in Veracyte is now worth
$ 104.28
giving a profit of
$ 4.28 (4.28%)
Note: Past profits do not guarantee future returns.
